HealthNotableSingle-source
5.2
Hypera launches Semavy, its GLP-1 rival to Ozempic, in Brazil
Valor Econômico·BR·about 20 hours ago
Fake versions of an investigational weight-loss drug are proliferating on the black market, preying on demand before regulatory approval. The scale of the counterfeit supply chain and the drug's safety profile remain unverified. This highlights risks to public health and potential reputational damage to the legitimate manufacturer.